2002
Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma
Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma. Cancer 2002, 94: 665-672. PMID: 11857298, DOI: 10.1002/cncr.10217.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaHigh dosesPelvic irradiationProstate carcinomaArm IFrequency of thrombocytopeniaLow-dose glucocorticoidsArm IIPhase II trialPhase III trialsPhase III testingMedian survival timeGranulocyte-macrophage colony-stimulating factorColony-stimulating factorAssessable patientsEstramustine combinationsII trialIII trialsMedian survivalPartial responsePSA valuesFavorable outcomeSurvival timePatientsSame schedule
1985
Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone MarrowCytarabineFemaleHumansLeukemia, Myeloid, AcuteLeukopeniaMaleMyeloproliferative DisordersThrombocytopeniaConceptsLow-dose cytosineAcute myelogenous leukemiaMyelodysplastic syndromeMyelogenous leukemiaTransient hematologic toxicityPeripheral blood countsAppropriate clinical roleTransfusion requirementsHematologic toxicityPartial responseDecreased incidenceBlood countClinical roleLow dosagePatientsSyndromeLeukemiaInfectionIncidenceCessation